Articles On MGC Pharmaceuticals (ASX:MXC)

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

“Outstanding” pivotal trial results paves the way for Orthocell to seek US approval for its Remplir nerve wrap Percheron promises Duchenne trial results by Christmas Argent Biopharma says it’s not goodbye – or au revoir   Orthocell (ASX:O...

Argent Biopharma packs its bags for London on a one-way ticket Patrys shares slump 50% on cancellation of key drug program Painchek targets US market for its pain detection app   Health Check is renowned biotech journo Tim Boreham’s daily...

Argent Biopharma plans further trials of its cannabinoid-based epilepsy treatment  Argent’s early research work suggests “improved safety profile alongside enhanced efficacy.” The first patient in Dimerix’s pivotal kidney trial enters open...

MGC Pharmaceuticals has officially rebranded to Argent BioPharma Strategic renaming follows infusion of capital and an operational overhaul Company looking to establish itself as a leader in polypharmacology   Special Report: Cannabis pla...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today. The telecommu...

MGC Pharmaceuticals completes share consolidation, ~US$8 million capital raise Company says it’s fully funded and well-positioned to proceed with pharmaceutical work plan for 2024 Has achieved ‘remarkable milestones over the past year’  ...

MGC Pharmaceuticals secures US$7.9 million in firm commitments in well supported capital raise Funds raised to serve as minimum required funding to support 12-month business plan MGC focused on US Food and Drug Administration IND applicati...

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

Benchmark ASX index ends +0.21%, but down -2.2% this week Consumer stocks offset Tech losses Small caps led by Webcentral    The benchmark has ended another tortuous week of trade with a little Friday victory. Down -2.2% for the week, all...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

Stockhead’s Top 10 at shortly-before-11-ish, produced in something of a grumbly mood this morning after I woke up today, stretched and felt wonderful as I looked forward to a quiet Saturday sleep-in, then realised it’s Thursday and well pas...

Stockhead’s Top 10 at shortly-before-11-ish, published after I’ve had a chance to look over the numbers from the handful of short, fleeting minutes that the market’s been open, while quietly having a life-altering blast of existential panic...

Several ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their cannabinoid products BOD Australia could have the first Schedule 3 CBD product in Australia following positive results from its Phase 2B Ca...

Stockhead’s Top 10 at shortly-before-11-ish, published once you’re all sitting nice and quietly each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live (not frozen!) data. It’s a short, sharp upda...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The US is about to follow Australia’s footsteps and approve psychedelics The FDA is currently awaiting a pivotal survey conducted by MAPS And here’s how the ASX weed stocks have performed over the past week   In July of this year, Austral...

Positive results from pre-clinical chronic toxicology evaluation of MGC Pharma’s CimetrA® in pigs supports previous data in an important step for its planned IND submission with the US FDA. European based Biopharma MGC Pharmaceuticals (ASX:...

Anteris Tech’s DurAVR THV was implanted successfully in a procedure Imugene moves forward to cohort 4 in VAXINIA study MGC Pharma says CimetraA has no toxicology profile in large animals   Anteris’ DurAVR THV implanted successfully Anteri...

MGC Pharmaceuticals has secured the first import permit for 200g of psilocybin raw mushroom material to its Slovenian research facility from Psyence Group’s Southern Africa production site, as part of the material transfer agreement signed...

What a time to be alive. As the clock struck midnight to herald the start of the 23/24 financial year, Australia’s ability to legally prescribe through qualified medical practitioners MDMA (ecstasy) and psilocybin – the active ingredient in...

MGC Pharmaceuticals has conditionally raised £0.65 million ($1.24 million) via a placement and subscription at 0.12 pence (0.23 cents) per share to provide a nice working capital runway for its short-term financing obligations. This price...

MGC Pharma has received a vote of confidence in ArtemiC after receiving a second order worth US$1m for the over the counter anti-inflammatory and treatment for moderate COVID 19 from AMC Pharma. AMC’s latest order, which has been secured wi...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The world is experiencing a ‘shroom boom’ Psychedelics are expected to follow in cannabis’ explosive footstep And here’s how the ASX weed stocks have performed, sorted by winners over the past week   For years, people have frowned upon ps...

MGC Pharmaceuticals’ Investigational Medicinal Product (IMP) CannEpil has been successfully imported and received by its first patients in the United Kingdom. CannEpil is a high-CBD, low-THC formulation, delivered by an oral mucosal solutio...

ShareCafeASX closes 1.2% lower as RBA hikes rates by 25 basis points by Peter Milios   Following the Reserve Bank’s decision to raise the cash rate to 3.85 per cent, the S&P/ASX 200 closed 0.92 per cent lower at 7,267.40, with losses ex...

ShareCafeQantas hires a new CEO: ASX down 0.22% at noon by Peter Milios   At noon, the S&P/ASX 200 is 0.22 per cent lower at 7,318.50, due to weakness in the industrials and consumer staples sectors. Qantas shares (ASX:QAN) were among t...

02 May 2023 - A snapshot of the stocks on the move featuring MGC Pharmaceuticals (ASX:MXC), Vitura Health (ASX:VIT) and Labyrinth Resources (ASX:LRL).

MGC Pharma’s recently-acquired  EU-Good Manufacturing Practice (GMP) certification will allow the company to sell in the US, and provide third party production services to other pharmaceutical companies. European-based biotech MGC Pharma (A...

ShareCafeStocks of the Hour: MXC, VIT, LRL                    MGC Pharmaceuticals (ASX:MXC) announced that their Malta production facility has been granted formal EU-Good Manufacturing Practice (GMP) certification. In response, Roby Z...

MGC Pharma says the breakthrough in the UK will allow CannEpil to be made available to a wide cohort of specialist medical practitioners in the UK.  European-based  biotech MGC Pharma (ASX:MXC) has made a breakthrough in the UK after its pr...

Post-Easter burst of zeal sees the ASX 200 up 1.3% at close Materials (+2.1%) outperformed by continued lust for Goldies (+2.9%) Prospech goes bonkers to +200%, before easing to “only” +155% for the day   Despite the ASX 200 April futures...

The number of Aussies using legal instead of illicit medical cannabis is rising The main reason for using prescribed medicinal cannabis was chronic pain, says Sydney Uni survey We take a look at what made the news in ASX weed stocks this p...

The approval in Slovenia will allow MGC Pharma to become one of the first movers in the burgeoning space of psychedelics. MGC Pharma (ASX:MXC) is set to  expand its European footprints further after receiving permission from the Slovenian M...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX climbed as high as +1.3%, easing slightly to close up 0.9%. XEC Emerging Companies and Goldies duke it out to see who can close flattest. Investors are set to pocket $35 billion in dividends between now and EOFY.   Do Not Adjust Your...

ShareCafeRebound in financial stocks boosts ASX 0.82% by Peter Milios   The sharemarket had a positive day on Tuesday, finishing 0.82 per cent higher at 6,955.40, with the financials sector leading the way with a 1.2 per cent gain. Macquari...

21 Mar 2023 - A snapshot of the stocks on the move featuring Besra Gold (ASX:BEZ), Mincor Resources (ASX:MCR), MGC Pharmaceuticals (ASX:MXC) and Renegade Exploration (ASX:RNX).

Firebrick Pharma reopens recruitment for Phase 3 trial MGC Pharma given OTC status in FDA’s NDC database Chimeric received positive feedback from the FDA   Firebrick Pharma (ASX: FRE) surged 7% this morning after announcing that its Phase...

ShareCafeASX up 1.3% at noon as UBS makes large forecasts by Peter Milios   According to UBS analysts, peak food inflation at Australian supermarkets Coles (ASX:COL) and Woolworths (ASX:WOW) likely occurred during the December 2022 Christma...

ShareCafeStocks of the Hour: BEZ, MCR, MXC, RNX                    Besra Gold (ASX:BEZ) has announced an up to US$300m for a non-binding drawdown offtake funding facility term sheet, signed with major shareholder Quantum Metal Recover...

The inclusion of MGC Pharma’s ArtemiC into the FDA’s NDC database will fill an important hole in the market between existing OTC products and expensive Big Pharma drugs. European based MGC Pharma (ASX:MXC) is set to expand its addressable...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Perth-based Brookside Energy (BRK) has delivered “extraordinary” early production and sales results from its Wolf Pack well, located within the world-class Anadarko Basin in the United States. The Wolf Pack well produced over 40,000 barr...